FDA cleared growth NeuMoDx recently received FDA 510(k) clearance for its GBS Assay, signaling a validated, compliant platform with a clear downstream expansion path into obstetrics and infectious disease testing, presenting a ready-to-sell regulatory milestone to target labs focusing on prenatal care and maternal health.

Automated high throughput The NeuMoDx 288 and 96 systems offer fully automated, random-access, sample-to-result workflow with integrated robotics and microfluidics, enabling high throughput and reduced hands-on time. Sales conversations can stress productivity gains, lab capacity expansion, and labor efficiency for centralized laboratories and hospital networks.

Broad assay ecosystem A growing portfolio of CE-IVD and FDA-cleared assays (GBS, CMV, EBV, Hep B/C, Flu A/B/RSV/SARS-CoV-2) plus LDT support and general reagents creates cross-sell opportunities for labs seeking an end-to-end molecular platform, enabling bundled reagent and consumable sales alongside instrument adoption.

Strategic partnerships Past collaborations (such as with SelfScreen for HPV) and channel expansion via acquisitions highlight a market approach that can be leveraged to form new partnerships with labs and distributors in Europe and beyond, accelerating deployment of NeuMoDx platforms and tests.

Growth and financing signals With a revenue range of one to ten million and substantial funding, NeuMoDx demonstrates resilience and investor confidence, signaling potential for sales acceleration, co-marketing opportunities, and expanded capacity to meet rising demand for molecular diagnostics in centralized labs and hospital systems.